Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

por Cameron, D A, Anderson, A, Toy, E, Evans, T R J, Le Vay, J H, Kennedy, I C S, Grieve, R J, Perren, T J, Jones, A, Mansi, J, Crown, J, Leonard, R C F
Publicado 2002